BioAtla, Inc.
Close on Oct 19, 2026
- Market cap
- $2.18M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | During market hours | – | $-0.27 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | During market hours | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | During market hours | – | $-0.26 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | $-0.44 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 26, 2024 | During market hours | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 7, 2023 | During market hours | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 1, 2023 | During market hours | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 11, 2023 | During market hours | – | – | – |
Press releases
Announcements BioAtla filed with the SEC
(Pursuant to Section 251 of the
Other events · EX-99.1 to Form 8-K
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation March 2026 Conditionally Active Biologics: Transforming Cancer Therapy
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE DATED MARCH 2, 2026
Results of operations · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Results of operations · EX-99.1 to Form 8-K
BIOATLA REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
BIOATLA REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
BIOATLA REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
BIOATLA, INC. ANNOUNCES REGISTERED DIRECT OFFERING TO ADVANCE
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Investor Presentation Non-Confidential December 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
BIOATLA REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
BIOATLA REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
BIOATLA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
BIOATLA REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Important Notices & Disclaimers This presentation (the
Regulation FD disclosure · EX-99.1 to Form 8-K
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BIOATLA REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
BIOATLA REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
BIOATLA REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
BIOATLA REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
Results of operations · EX-99 to Form 8-K